News & Events

Regulation FD Disclosure On April 24, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that an unauthorized third party had accessed data in certain of the Company’s information technology (“IT”) systems. Upon identifying the unauthorized access, the Company promptly took steps to contain the incident, activated its incident response protocols, and engaged leading external cybersecurity experts to support its investigation and remediation efforts. Based on its investigation to dat…

Regulation FD Disclosure On March 18, 2026, MiniMed Group, Inc. (MiniMed), a consolidated subsidiary of Medtronic plc (Company) announced that the U.S. Food and Drug Administration (FDA) has cleared the MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump. The clearance of the MiniMed Flex by the FDA was several months earlier than anticipated, and will facilitate the earlier commercialization of this key MiniMed product. The research and development of the MiniMed Fl…

Results of Operations and Financial Condition On February 17, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 1, 2025, Gregory L. Smith, Executive Vice President, Enterprise Operations of Medtronic plc (the Company), notified the Company of his decision to retire from the Company, effective December 2, 2025, and to join a private equity-held organization. As of that date, Mr. Smith will be eligible for retirement treatment of his outstanding eq…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Transition of Principal Accounting Officer On March 12, 2025, Jennifer M. Kirk, the Global Controller and Principal Accounting Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective May 2, 2025, to become the chief executive officer of Exubrion Therapeutics, a privately held company. Ms. Kirk’…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the previously announced appointment of Gary Corona as the Company’s interim Chief Financial Officer, the Compensation Committee approved the following compensatory arrangement for Mr. Corona on August 15, 2024: (i) a bi‑weekly cash stipend in the amount of $12,500, effective as of August 3, 2024 and (ii) an equity grant of 8,966…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 1, 2024, Rob ten Hoedt, Executive Vice President and President, Global Regions of Medtronic plc (Company), notified the Company of his decision to retire from the Company, effective as of June 28, 2024. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on…

Regulation FD Disclosure On March 9, 2023, Medtronic plc became aware that a third party erroneously communicated to various data providers including Bloomberg a notice of redemption for the 0.000% Senior Notes due 2025 issued by Medtronic Global Holdings S.C.A. (“Medtronic Luxco”). That communication was subsequently made available by various sources more broadly. Medtronic Luxco has not issued a notice of redemption for these notes. SIGNATURES Pursuant to the requirements of the Securities…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 14, 2021, Richard Kuntz, M.D. notified Medtronic plc (the “Company”) that he had decided to retire as Senior Vice President and Chief Medical and Scientific Officer of the Company, effective as of April 29, 2022. Dr. Kuntz has been a member of the Company’s executive committee since 2005, and will retire following an over 15-year tenure…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. This Current Report on Form 8-K contains forward-looking statements within the meaning of the P…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Bradley E. Lerman to retire as Senior Vice President, General Counsel and Corporate Secretary On June 24, 2021, Bradley E. Lerman notified the board of directors of Medtronic plc (the “Company”) that he had decided to retire as Senior Vice President, General Counsel and Corporate Secretary of the Company, effective as of December 31, 2021. Mr. Lerman has been a member of the Company’s execu…